Kevin B. Bacon, Ph.D.
Founder, CSO and Head of Research & Development

Dr. Bacon founded Actimis as a spin-off from Bayer Yakuhin Ltd.’s Respiratory Research Department in Kyoto, Japan. Dr. Bacon was most recently Vice President for Respiratory diseases research with line and matrix management responsibilities for respiratory small molecule therapeutic development company-wide. Dr. Bacon was also involved in establishing and managing major corporate collaborations and partnerships (Oxford Glycosciences, Entelos, Lion, Galapagos Genomics, Inc., as well as numerous academic and Institutional collaborations). Prior to joining Bayer in 1999, Dr. Bacon was Associate Director of Immunology at Neurocrine Biosciences, Inc., in San Diego, and from 1994 to 1997 a Visiting Scientist at the DNAX Institute for Molecular Biology (a subsidiary of Schering Plough), in Palo Alto. Dr. Bacon received his B.Sc. and Ph.D. in Pharmacology from the University of London (King’s College and United Medical and Dental Schools of Guy’s and St. Thomas’, respectively) and following post-doctoral studies, joined the Glaxo Institute for Molecular Biology (now Serono) in Geneva, Switzerland as a staff scientist focused on inflammation research. Dr. Bacon has published over 100 original manuscripts, book chapters and reviews and has been a regular contributor of original research to the field of chemokine biology since its inception with specific interest, and pioneering many studies, in the signaling mechanisms of these molecules and their biological roles in cells of the immune system.

Taro Inaba

Mr. Inaba is Head of Global Bio-Pharma Team and Investment Partner at Mitsui Ventures responsible for investments in the biotechnology and life science spaces both in the US and Asia. He has seventeen years experience in investment and business development in both the life science and chemical industries.  He serves as a board member for Mitsui Ventures' three existing portfolio firms and is responsible for all the 12 Mitsui Ventures biotechnology and life science portfolio firms.  He holds a Bachelor of Engineering from Kyoto University and an MBA from European University in Lisbon, as well as a CFA charter.

Peter C. M. McWilliams, Ph.D.
Chairman and Acting Chief Executive Officer

Dr. McWilliams is a Principal of Sanderling Ventures, the lead investor of Actimis Pharmaceuticals, and brings with him more than fifteen years of experience in biomedical research and management. In addition to Actimis Pharmaceuticals, Dr. McWilliams also serves in the capacity of Director, Chief Executive Officer and member of the management team in several other Sanderling portfolio companies. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin™. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. From 1991 to 1994 he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, helping to set up and establish their US operations prior to their successful IPO on the London Stock Exchange in 1994. Dr. McWilliams received an M.B.A. from Columbia Business School in 1996, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. in 1991 and an M.A. in 1990 in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University in 1987.

Fred Middleton

Fred Middleton is a Managing Director of Sanderling Ventures and has over twenty-five years experience in the biotechnology and biomedical industries in both corporate management and as an institutional investor. Mr. Middleton joined Sanderling in late 1987 as a General Partner and since then he has focused on venture capital investments and the corporate development of early-stage biomedical companies, serving as a founder, management team member and director of numerous start-up ventures in the Sanderling portfolio. Over the last several years, he has played active management roles as Chairman, CEO or Director of a number of Sanderling portfolio companies. Mr. Middleton began his career as a consultant in McKinsey & Company's San Francisco office and was also a Vice President of Chase Manhattan Bank in New York. In 1978, Mr. Middleton joined Genentech, Inc. to become part of the original management team and served as Vice President of Finance, Administration, Corporate Development, as well as Chief Financial Officer. While at Genentech, Mr. Middleton completed over $200 million in corporate partnering and institutional funding transactions, including the Company's initial public offering in 1980. In 1984, Mr. Middleton founded Morgan Stanley Ventures, serving as managing general partner of an institutional fund raised to sponsor R&D funding arrangements at leading technology companies in the biomedical sciences and information technology fields. Mr. Middleton earned a B.S. in chemistry from the Massachusetts Institute of Technology in 1971 and an M.B.A with distinction from Harvard Business School in 1973.